ARD-69

• Target :

  Androgen Receptor|||PROTACs

• Related Pathways :

  PROTAC|||Endocrinology/Hormones

• Bioactivity :

  ARD-69 is a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, respectively. ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.

• Smiles :

  O=C([C@H]1N(C([C@@H](NC(C2(F)CC2)=O)C(C)(C)C)=O)C[C@H](O)C1)N[C@H](C3=CC=C(C4=C(C)N=CS4)C=C3)CC(N5CCC(N6CCC(C#CC7=CC=C(C(N[C@H]8C(C)(C)[C@H](OC9=CC=C(C#N)C(Cl)=C9)C8(C)C)=O)C=C7)CC6)CC5)=O

• Molecular Formula :

  C62H74ClFN8O7S

• Molecular Weight :

  1129.83

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C